Neuroendocrine tumors refer to a group of cancers that originate
from neuroendocrine cells of the body. These tumors can develop in several
organs like lungs, pancreas, intestine and stomach. Common symptoms include
easy bruising, abdominal pain, flushing or diarrhea. Treatment for
neuroendocrine tumors majorly includes surgery to remove the tumor, radiation
therapy to kill cancer cells and prevent tumor growth. Chemotherapy involves
use of drugs like streptozotocin and 5-fluorouracil to destroy cancer cells.
Some hormonal therapies aim to slow or stop tumor growth by blocking certain
hormones. Targeted drug therapies such as sunitinib and everolimus intervene
specific pathways that help cancer cells grow and spread.
The Global
Neuroendocrine Tumor Treatment Market is estimated to be valued at US$ 3.46 Bn
in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2024
to 2031.
Key Takeaways
Key players operating in the Neuroendocrine Tumor Treatment are Schott AG,
Yulong Dingtajian, Apex Solar, Sinosun Energy, Neo Solar Power Corporation,
Solimpeks Solar Energy, Sunrain, Hubei Fullhonor Solar Energy, and others. With
rising global incidence of neuroendocrine tumors, the need for effective
treatment options is growing significantly. Some major players are focusing on
development of targeted drug therapies to prevent tumor growth and metastatic
spread.
Growing demand in the market: The
Neuroendocrine
Tumor Treatment Market Trends
is rising primarily due to increasing incidence of neuroendocrine tumors
worldwide. According to estimates, neuroendocrine tumors annually affect around
5 people per 100,000. This unmet medical need is a major factor boosting
adoption of newer targeted therapies and combination regimen over conventional
chemotherapy.
Global expansion of market: Key neuroendocrine tumor treatment manufactures are
expanding their geographical presence through collaboration with local
distribution partners. For instance, In 2022, Solimpeks Solar Energy entered
into partnership with a South African company to distribute its products in
Africa. This helped enhance accessibility of neuroendocrine tumor therapies in
new potential markets.
Market key trends
The increased research in targeted drug therapies is a key trend witnessed in
the neuroendocrine tumor treatment market. Many pharmaceutical companies are
involved in development of small molecule inhibitors focused on receptor
tyrosine kinases and mTOR pathways. Agents like Cabozantinib, Olaparib and
Sorafenib shows promising results in clinical trials and are expected to be
available soon for treatment against specific neuroendocrine tumor types.
Porter’s
Analysis
Threat of new entrants: New pharmaceutical and biotechnology companies face
significant challenges in entering this market due to high capital requirements
and stringent regulatory approvals.
Bargaining power of buyers: Individual consumers have low
bargaining power as they seek access to novel and effective therapies to improve
treatment outcomes.
Bargaining power of suppliers: Suppliers of pharmaceutical
ingredients and raw materials have moderate bargaining power as there exist
substitutes and buyers negotiate prices and contracts.
Threat of new substitutes: Emerging therapies for NETs
represent potential substitutes but have not demonstrated superiority to
existing options.
Competitive rivalry: Competition among established
pharmaceutical companies is strong as they invest in R&D to introduce
innovative drugs and combination therapies that improve patient outcomes.
Geographically, North America dominates the neuroendocrine tumor treatment
market in terms of value. This is attributed to high awareness regarding rare
cancers, favorable reimbursement policies for innovative therapies, easy
regulatory pathways for clinical trials, and presence of key market players.
Asia Pacific represents the fastest growing regional market for NET therapies
owing to increasing burden of NETs, rising healthcare expenditure, and growing
popularity of precision cancer treatments.
Get More
Insights on- Neuroendocrine
Tumor Treatment Market
About
Author:
Priya Pandey is a dynamic and passionate editor with over
three years of expertise in content editing and proofreading. Holding a
bachelor's degree in biotechnology, Priya has a knack for making the content
engaging. Her diverse portfolio includes editing documents across different industries, including food
and beverages, information and technology, healthcare, chemical and materials,
etc. Priya's meticulous attention to detail and commitment to excellence
make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
Comments
Post a Comment